We are live on ! Find out more
AUTL

Autolus Therapeutics
AUTL

69 hedge funds and large institutions have $169M invested in Autolus Therapeutics in 2021 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 22 increasing their positions, 13 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

69% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 13

35% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 17

31% more capital invested

Capital invested by funds: $129M → $169M (+$39.9M)

10% more funds holding

Funds holding: 63 → 69 (+6)

4.29% more ownership

Funds ownership: 33.82% → 38.11% (+4.3%)

Holders
69
Holders Change
+6
Holders Change %
+9.52%
% of All Funds
1.2%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
23
Increased
22
Reduced
13
Closed
17
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$16.9M
2
FM
Frazier Management
Washington
+$14.2M
3
NCM
Nantahala Capital Management
Connecticut
+$11.1M
4
Goldman Sachs
Goldman Sachs
New York
+$3.97M
5
SCM
Sio Capital Management
New York
+$3.67M

Top Sellers

Rank Fund Capital Flow
1
Capital International Investors
Capital International Investors
California
-$13M
2
DM
Deerfield Management
New York
-$12.3M
3
OM
Opaleye Management
Massachusetts
-$12.1M
4
BBA
Baker Bros. Advisors
New York
-$2.65M
5
BlackRock
BlackRock
New York
-$1.51M
Name Holding Trade Value Shares
Change 		Change in
Stake
LC
51
Lindbrook Capital
California
$52K +$30.3K +4,882 +163%
Citigroup
52
Citigroup
New York
$22K +$16.3K +2,620 +402%
TRCT
53
Tower Research Capital (TRC)
New York
$17K -$3.07K -494 -16%
QCG
54
Quadrant Capital Group
Ohio
$15K +$14K +2,250 New
US Bancorp
55
US Bancorp
Minnesota
$11K +$5.64K +908 +136%
PCM
56
Penserra Capital Management
California
$8K +$2.85K +460 +60%
CFGS
57
Concourse Financial Group Securities
Alabama
$7K – – –
S
58
SignatureFD
Georgia
$3K +$2.58K +416 New
ED
59
Exane Derivatives
France
$1.14K – – –
Bank of America
60
Bank of America
North Carolina
$1K -$164K -26,385 -99%
Osaic Holdings
61
Osaic Holdings
Arizona
$1K -$35.7K -5,750 -98%
CAPTRUST Financial Advisors
62
CAPTRUST Financial Advisors
North Carolina
$1K +$993 +160 New
PA
63
Parallel Advisors
California
$1K +$1.12K +180 New
MGIM
64
M&G Investment Management
United Kingdom
$264 +$234K +37,705 New
BNP Paribas Financial Markets
65
BNP Paribas Financial Markets
France
$232 +$217 +35 New
Capital International Investors
66
Capital International Investors
California
– -$13M -2,272,728 Closed
DM
67
Deerfield Management
New York
– -$12.3M -2,142,857 Closed
OM
68
Opaleye Management
Massachusetts
– -$12.1M -2,112,918 Closed
BBA
69
Baker Bros. Advisors
New York
– -$2.65M -461,726 Closed
CCM
70
CAAS Capital Management
New York
– -$1.28M -223,366 Closed
LCM
71
Laurion Capital Management
New York
– -$876K -152,847 Closed
Squarepoint
72
Squarepoint
New York
– -$473K -82,602 Closed
Renaissance Technologies
73
Renaissance Technologies
New York
– -$467K -81,588 Closed
Two Sigma Investments
74
Two Sigma Investments
New York
– -$442K -77,140 Closed
California Public Employees Retirement System
75
California Public Employees Retirement System
California
– -$233K -40,600 Closed
1 2
3
4

AUTL Hedge Fund Activity: Q2 2021 in Review

69 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Autolus Therapeutics (AUTL) for Q2 2021, worth a combined $169M — up 31% from $129M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new AUTL positions and 17 closed out — a net gain of 6 holders — while 22 added to existing stakes and 13 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $16.9M. The largest seller was Capital International Investors, exiting entirely with an estimated $13M sold.

  • 69 institutional investors held Autolus Therapeutics (AUTL) as of Q2 2021, up from 63 in Q1 2021.
  • Funds reported $169M of Autolus Therapeutics stock for Q2 2021, up 31% quarter-over-quarter.
  • 23 funds opened new Autolus Therapeutics positions in Q2 2021 and 17 closed out, a net change of +6 holders.
  • The largest Autolus Therapeutics buyer in Q2 2021 was Citadel Advisors, an estimated $16.9M added.
  • The largest Autolus Therapeutics seller in Q2 2021 was Capital International Investors, an estimated $13M sold.

Based on aggregated 13F filings for Q2 2021.